Relative Bioavailability of Olodaterol and Fluconazole

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: June 29, 2010
Last updated: May 4, 2011
Last verified: May 2011

This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: BI 1744
Drug: Fluconazole
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Relative Bioavailability of 10 Mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The objective of the current study is to investigate whether and to what extent the CYP 2C9 inhibitor fluconazole affects systemic exposure to olodaterol [ Time Frame: whole study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The assessment of safety and tolerability of olodaterol and fluconazole upon co-administration is secondary objective of the present trial [ Time Frame: whole study ] [ Designated as safety issue: Yes ]

Enrollment: 35
Study Start Date: May 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 1744 10 mcg
solution for oral inhalation
Drug: BI 1744
10 mcg solution for oral inhalation
Drug: Fluconazole
400 mg capsule
Experimental: Fluconazole 400 mg
capsule (800 mg loading dose)
Drug: BI 1744
10 mcg solution for oral inhalation
Drug: Fluconazole
400 mg capsule


Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

Healthy male and female volunteers

  Contacts and Locations
Please refer to this study by its identifier: NCT01153724

1222.48.1 Boehringer Ingelheim Investigational Site
Berlin, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT01153724     History of Changes
Other Study ID Numbers: 1222.48, 2010-018528-18
Study First Received: June 29, 2010
Last Updated: May 4, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Lung Diseases, Obstructive
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 22, 2014